Myeloid Growth Factors for Bendamustine and Rituxan regimen – pro
NCCN does not use this regimen amongst dose that have intermediate to high risk of febrile neutropenia and required growth factor support. In general, and CCN as well as other guidelines, require a risk of febrile neutropenia of 20% to justify myeloid growth factors. In a recent stud in patients with indolent NHL, in front-line treatment with bendamustine plus rituximab, primary prophylaxis with pegfilgrastim seems to reduce the incidence of chemotherapy disruptions due to FN, and the days of hospitalization.However, rate of FN-related chemotherapy disruptions was on the 11.4% in the control group. ThereforeGranix support is not medically necessary.
NCCN, Myeloid Growth Factors, 2017.
Claudio Cerchione et al,Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. Support Care Cancer. 2017; 25(3): 839845.